Suppr超能文献

一种评估毛细管微采样替代临床研究中静脉采样可行性的药物代谢动力学方法:以他非诺喹为例。

A pharmacometrics approach to assess the feasibility of capillary microsampling to replace venous sampling in clinical studies: Tafenoquine case study.

机构信息

Clinical Pharmacology Modeling and Simulation, GSK, Collegeville, PA, USA.

Drug Metabolism and Pharmacokinetics, In Vitro/In Vivo Translation, R&D GSK, Ware, Herts, UK.

出版信息

Br J Clin Pharmacol. 2023 Mar;89(3):1187-1197. doi: 10.1111/bcp.15554. Epub 2022 Nov 9.

Abstract

AIM

Microsampling has the advantage of smaller blood sampling volume and suitability in vulnerable populations compared to venous sampling in clinical pharmacokinetics studies. Current regulatory guidance requires correlative studies to enable microsampling as a technique. A post hoc population pharmacokinetic (POPPK) approach was utilized to investigate blood capillary microsampling as an alternative to venous sampling.

METHODS

Pharmacokinetic data from microsampling and venous sampling techniques during a paediatric study evaluating tafenoquine, a single-dose antimalarial for P. vivax, were used. Separate POPPK models were developed and validated based on goodness of fit and visual predictive checks, with pharmacokinetic data obtained via each sampling technique.

RESULTS

Each POPPK model adequately described tafenoquine pharmacokinetics using a two-compartment model with body weight based on allometric scaling of clearance and volume of distribution. Tafenoquine pharmacokinetic parameter estimates including clearance (3.4 vs 3.7 L/h) were comparable across models with slightly higher interindividual variability (38.3% vs 27%) in capillary microsampling-based data. A bioavailability/bioequivalence comparison demonstrated that the point estimate (90% CI) of capillary microsample versus venous sample model-based individual post hoc estimates for area under the concentration-time curve from time zero to infinity (AUC ) (100.7%, 98.0-103.5%) and C (79.7%, 76.9-82.5%) met the 80-125% and 70-143% criteria, respectively. Overall, both POPPK models led to the same dose regimen recommendations across weight bins based on achieving target AUC.

CONCLUSIONS

This analysis demonstrated that a POPPK approach can be employed to assess the performance of alternative pharmacokinetic sampling techniques. This approach provides a robust solution in scenarios where variability in pharmacokinetic data collected via venous sampling and microsampling may not result in a strong linear relationship. The findings also established that microsampling techniques may replace conventional venous sampling methods.

摘要

目的

与静脉采样相比,微量采样在临床药代动力学研究中具有采血量少、适用于脆弱人群的优势。目前的监管指南要求进行相关性研究,以使微量采样成为一种技术。本研究采用事后群体药代动力学(POPPK)方法,研究血液毛细血管微量采样作为静脉采样的替代方法。

方法

本研究使用了一项评估tafenoquine(一种用于治疗间日疟原虫的单剂量抗疟药)的儿科研究中,通过毛细血管微量采样和静脉采样技术获得的药代动力学数据。根据拟合度和可视化预测检查,分别建立和验证了基于体重的基于体表面积的两室模型的单独 POPPK 模型,该模型对清除率和分布容积进行了比例缩放。tafenoquine 药代动力学参数估算值,包括清除率(3.4 与 3.7 L/h),在基于毛细血管微量采样数据的模型中具有可比性,而毛细血管微量采样数据的个体间变异性略高(38.3%与 27%)。生物利用度/生物等效性比较表明,毛细血管微样本与静脉样本模型的个体事后估计的 AUC(100.7%,98.0-103.5%)和 C(79.7%,76.9-82.5%)的点估计值(90%CI)符合 80-125%和 70-143%标准。总体而言,基于实现目标 AUC,两种 POPPK 模型都在不同体重组中推荐了相同的剂量方案。

结论

该分析表明,POPPK 方法可用于评估替代药代动力学采样技术的性能。在通过静脉采样和微量采样收集的药代动力学数据存在较大差异,且不能产生较强线性关系的情况下,该方法提供了一种可靠的解决方案。研究结果还表明,微量采样技术可能替代传统的静脉采样方法。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验